Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GIP for blood glucose control in critically ill patients
ACTRN12612000488808Phase 2Recruiting
- Sponsor
- Adam Deane
- Start
- Apr 2012
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2 trial of glucose-dependent insulinotropic polypeptide[1-42] in critical illness and hyperglycemia (2 arms), sponsored by Adam Deane. Primary endpoint: Fasting and nutrient-stimulated glycemia. Started Apr 2012; status: recruiting.
02
Drugs
glucose-dependent insulinotropic polypeptide[1-42]
03
Conditions
critical illnesshyperglycemia
Beyond the preview
Go deeper on ACTRN12612000488808.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12612000488808.